Characteristics and Outcomes of Intracranial Hemorrhage in Cancer Patients Visiting the Emergency Department

Aiham Qdaisat  
The University of Texas MD Anderson Cancer Center

Sai-Ching Yeung  
The University of Texas MD Anderson Cancer Center

Cristhiam M Rojas Hernandez  
The University of Texas MD Anderson Cancer Center

Pavani Samudrala  
The University of Texas MD Anderson Cancer Center

Mona Kamal  
The University of Texas MD Anderson Cancer Center

Ziyi Li  
The University of Texas MD Anderson Cancer Center

Adriana H. Wechsler (✉ ahwechsler@mdanderson.org)  
The University of Texas MD Anderson Cancer Center

Research Article

Keywords: Cancer, intracranial hemorrhages, emergency, mortality, platelet count, characteristics.

DOI: https://doi.org/10.21203/rs.3.rs-776084/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction: Intracranial hemorrhage is a devastating complication of cancer and its treatment.

Objective: To evaluate the characteristic, risk factors and clinical outcomes in cancer patients with intracranial hemorrhage presenting to the emergency department.

Methods: We collected a decade of retrospective data on all patients with the diagnosis of ICH who visited The University of Texas MD Anderson Cancer Center emergency department. Logistic regression analyses were used to determine the association between clinical variables and various outcomes.

Results: 704 confirmed acute ICH cases were identified. Of these, 576 (81.8%) were spontaneous. In-hospital, 7-day, and 30-day mortality rates were 15.1%, 11.4%, and 25.6%, respectively. Hypertension was most predictive of prolonged hospital stay (\[OR\]=4.77, 95% CI=1.30-22.70, \(P=0.045\)) and intensive care unit admission (\(OR=1.52, 95\% \text{ CI}=1.09-2.12, P=0.013\)). Low platelet count was associated with both in-hospital mortality (\(OR=0.96, 95\% \text{ CI}=0.94-0.99, P=0.008\)) and 30-day mortality (\(OR=0.98, 95\% \text{ CI}=0.96-1.00, P=0.016\)). Radiologic findings especially herniation and hydrocephalus, were strong predictors of short-term mortality. Patients with intratumor bleeding had substantially lower short-term mortality rates, but this did not reach statistical significance.

Conclusions: Intracranial hemorrhage remains an uncommon complication in cancer patients. The risk factors most helpful in predicting outcomes were hypertension, low platelet count, and hydrocephalus or herniation on imaging.

Introduction

Intracranial hemorrhage (ICH) is a dreaded complication of both cancer and its treatment. In the general population, intracerebral hemorrhage represents only 10-20% of strokes but is more deadly, with a reported case fatality ratio of 24-37% at 7 days and 40-59% at 30 days [2, 5, 10, 12, 15, 23]. Among cancer patients, both the incidence of ICH and ICH-associated mortality rates are assumed to be increased, heightening the need for a clear understanding of the characteristics of cancer patients with ICH and how these characteristics affect outcomes.

Studies to date have been limited in terms of either inclusion criteria or scope of variables investigated, such that the relative contribution of specific variables to outcomes is not discernable. Examining a large database of hospitalized patients, Murthy et al concluded that cancer patients with ICH had higher in-hospital mortality rates and higher morbidity rates than non-cancer patients. However, patients with cerebral metastases or primary brain tumors were excluded from that analysis. Some studies considered only liquid tumors or primary CNS tumors thus increasing susceptibility to bias effects [3, 6, 17, 25]. Other studies focus on one risk factor, such as anticoagulation therapy, without consideration for its interplay with others [3, 7].
In the current study, we take a more comprehensive look at the characteristics, management, and clinical outcomes of ICH in cancer patients presenting to the emergency department (ED) of a dedicated cancer center. Our large cancer population allowed us to discriminate outcomes by cancer type, presence of metastases, and presence of risk factors. Understanding which patient characteristics and risk factors carry the best prognosis can help ED physicians identify the patients most vulnerable to ICH and expedite appropriate evaluation and management in those first critical hours of hematoma expansion. Alternatively, identifying the patients least likely to survive can limit aggressive interventions that may be futile and instead turn attention to goals of care.

**Methods**

**Study participants and data collection**

Under an approved institutional review board protocol, we performed a retrospective cohort study of all consecutive patients who visited the ED of The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, between September 1, 2006, and February 16, 2016, with a diagnosis of ICH. Eligible cases were identified from the institutional billing database using all ICH related ICD-9 and ICD-10 codes. Exclusion criteria were 1) age younger than 18 years, 2) no cancer diagnosis, 3) no acute ICH present, 4) ICH diagnosed at another institution, 5) patients transferred out, and 6) missing ED physician notes.

Cases were reviewed by four independent investigators using the electronic medical record system and a defined data dictionary. All investigators were trained on data extraction and used a standardized form to guide data collection. Finally, fifty charts were randomly selected and reviewed by a different abstractor than the original abstractor to assess the interrater agreement, reporting the Cohen's kappa coefficient (κ). Patient demographics, clinical and laboratory findings, cancer-related factors, and comorbidities that are known to be associated with ICH were collected through chart review. Imaging reports were reviewed for confirmation of acute ICH, defined as a subdural, epidural, intraparenchymal, or subarachnoid bleed, as well as hemorrhagic brain tumor, found on diagnostic brain CT or MRI within 24 hours of the ED visit. The first available value for the laboratory studies was used for the analysis as continuous variables.

**Statistical analysis**

Descriptive statistics were used to describe and compare the characteristics of the cohort. Significance was appraised using the chi-square test, Fisher’s exact test, Student’s *t* test, or non-parametric tests (Wilcoxon-Mann-Whitney test) when normality assumption was not met. Univariate logistic regression analysis was used to determine the association between each of the clinical and cancer-related variables and ICH outcomes. Significant variables from the univariate analyses were further analyzed using a multiple logistic regression model. A two-tailed *P* value <0.05 was considered statistically significant. All
statistical analyses were performed using R software (version 3.6.3, The R Foundation, http://www.r-project.org).

Results

Characteristics of cancer patients with ICH presenting to an oncologic ED

During the 10-year period studied, 77,925 unique cancer patients made 204,464 ED visits to a large, urban National Cancer Institute–designated comprehensive cancer center serving mostly oncology patients. A total of 704 patients had confirmed acute ICH once the eligibility criteria were applied (0.34% of ED visits). The kappa coefficient (κ) for the interrater agreement was 0.873 indicating very-good agreement between different abstractors. Among the 704 patients with confirmed acute ICH, 128 (18.2%) had traumatic ICH and the remaining 576 (81.8%) had spontaneous ICH (Figure 1). Headache (42.2%) and altered mental status (35.9%) were the most common presenting symptoms (Table S1).

The most common underlying cancer types were leukemia (27.8%) and melanoma (17.5%). Most of the patients (88.8%) had active cancer. Patients with traumatic ICH were significantly older than those with spontaneous ICH (median age 66 years compared with 59 years; \( P < 0.001 \)). Furthermore, history of hypertension (53.1% compared with 42.4%; \( P = 0.034 \)), hypercholesterolemia (28.1% compared with 17.4%; \( P = 0.008 \)), and hematologic malignancies (54.7% compared with 31.3%; \( P < 0.001 \)) were observed significantly more frequently among patients with traumatic ICH than among those with spontaneous ICH (Table 1).

Subdural hematoma was the most common (35.2%) location for ICH. Other frequent locations were hemorrhagic metastasis (28.3%), intraparenchymal hemorrhage (10.5%), and subarachnoid hemorrhage (8.8%). Common associated imaging findings were edema (47.2%) and midline shift (34.2%). Ninety-three patients (13.2%) had herniation and 77 patients (10.9%) had associated hydrocephalus (Table S2). Melanoma (47.2%) and lung cancer (18.6%) were the most common primary tumors associated with intracranial metastatic hemorrhagic lesions (Table S3). Intra-metastatic bleeding was associated with lower incidence of midline shift and herniation (Table S4)

Most patients were admitted to either a hospital ward (50.6%) or intensive care unit (ICU; 41.5%). Thirty-five patients (5%) were discharged to home or a hospice, only 6 (0.9%) were directly transferred to the operating room for surgery, and 4 (0.6%) died in the ED. Treatment was initiated in most patients (93.8%), and platelet transfusion was the most common treatment modality (30%), followed by dexamethasone (20.3%) whereas early surgical intervention was uncommon (11.7%, Table 2).

Risk factors for ICU admission and prolonged hospital stay in cancer patients with ICH
The median hospital length of stay for the whole population was 5 days, and it was significantly higher in patients with traumatic ICH than in those with spontaneous ICH (6 days compared with 5 days; \( P = 0.007 \)). Among the 292 patients (41.5%) who were admitted to the ICU (Table 2), 230 had spontaneous ICH, representing 39.9% of the spontaneous ICH group (230/576), and 62 had traumatic ICH, representing 48.4% of that group (62/128). The median ICU length of stay was 2 days for both subgroups (Table 2).

History of hypertension and low platelet count were associated with longer hospital stay (hypertension: odds ratio [OR] = 4.77, 95% confidence interval [CI] = 1.30-22.70, \( P = 0.045 \); low platelets: OR = 0.93, 95% CI = 0.87-1.00, \( P = 0.041 \); Table 3 and Table S5). Hypertension was also associated with an increased likelihood of being admitted to the ICU (OR = 1.52, 95% CI = 1.09-2.12, \( P = 0.013 \)), and intratumor bleeding was associated with a decreased likelihood of being admitted to the ICU (OR = 0.66, 95% CI = 0.45-0.97, \( P = 0.033 \)). Patients with a platelet count less than 50 had significantly longer hospital stay and ICU admission (OR = 27.96, 95% CI = 5.20-150.4, \( P < 0.001 \) and OR = 2.22, 95% CI = 1.60-3.09, \( P < 0.001 \); respectively).

**Mortality in cancer patients with ICH**

One hundred six patients (15.1%) died during their hospital stay. Seven-day and 30-day mortality rates were 11.4% and 25.6%, respectively (Table 2). Multiple myeloma, sarcoma, gastrointestinal tumors, and leukemia had the highest 7-day and 30-day mortality (Table S6). In the univariate analysis, several clinical factors were associated with short-term mortality (Table S7). Significant variables from the univariate analysis were further investigated using a multivariable logistic regression model (Figure 2). Platelet count and hemoglobin level were significant factors that predicted short-term mortality. Low platelet count was associated with increased in-hospital mortality rate (OR = 0.96, 95% CI = 0.94-0.99, \( P = 0.008 \)) and 30-day mortality rate (OR = 0.98, 95% CI = 0.96-1.00, \( P = 0.016 \)), indicating that a drop in platelet count by a magnitude of 10 increased the risk of mortality by 2-4%. Similar results were observed when the platelet count was categorized using a cutoff point of 50 (table S7). In the same manner, low hemoglobin level was associated with increased 30-day mortality rate (OR = 0.90, 95% CI = 0.82-0.98, \( P = 0.019 \)), but not with in-hospital or 7-day mortality rates.

To determine the effect of various radiologic features on short-term mortality, we constructed additional logistic regression models (Table S8 and Table 4). As each radiologic feature correlated with the others (\( P < 0.001 \) for all), and to prevent multicollinearity in the model, we constructed logistic regression models for each radiologic feature separately, controlling for platelet count, hemoglobin level, and intratumor bleeding (Table 4). Midline shift, edema, herniation, and hydrocephalus were all significantly associated with an increased risk of short-term mortality after adjusting for platelet count, hemoglobin level, and intratumor bleeding; the presence of herniation or hydrocephalus dramatically altered the risk (adjusted odds ratio [AOR] = 10.63, 95% CI = 6.18-18.48, \( P < 0.001 \)) and (AOR = 5.78, 95% CI = 3.19-10.39, \( P < 0.001 \)) respectively for the 7-day mortality.
Discussion

To the best of our knowledge, our population is the largest cohort of cancer patients with ICH to be studied to date, with more than 700 patients, compared with 208 in a 2010 study from another cancer center [18]. ICH remains an uncommon diagnosis for cancer patients despite their increased risk. Only 0.34% of all ED visits over the 10-year period studied involved ICH. Our cancer population also had a significantly lower inpatient mortality rate (15.1%) than previously reported (37.3%) in a large hospital database review of cancer patients from 2016, roughly the same period as our study. [17] The higher mortality rate in the hospital study may be a result of the exclusion of patients with brain tumors since we found that patients with intratumor bleeding often had a shorter hospital stay and lower rates of ICU admission and in-hospital mortality, and 7-day mortality. Hemorrhage into metastases was the most common site of bleeding in patients with spontaneous ICH. Intratumor bleeding also appeared to be more benign in terms of 30-day mortality rates, according to our multivariable analysis, similar to previous reports [18]. We hypothesize that intra-metastatic bleeding prognosticates a more benign course because they are often smaller and better accommodated in the fixed cranial space. Although we do not have volumetric measurements of the bleeding due to variability of reporting in this retrospective review, we used the presence of herniation or midline shift as a surrogate marker for larger, space occupying bleeds.

Patients with traumatic ICH tended to be older, and proportionally more of them had hematologic malignancies. The most common location by far was subdural hematoma (61.7%) since subdural bleeds tend to be provoked by trauma, and the thrombocytopenia accompanying leukemia places these patients at greater risk. Perhaps our prophylactic transfusion strategies were effective in preventing spontaneous but not traumatic ICH. Traumatic ICH also resulted in slightly higher ICU admission rates and significantly longer hospital stays, reflecting more severe or complication-laden bleeds.

The in-hospital mortality rate was 15.1% overall for our patients, close to the 22% noted in the Navi et al study from 2010, which, like our cohort, included patients with brain metastases and primary brain tumors [18]. As in our study, Murthy et al reported that the 7-day mortality rate from ICH was almost twice as high in patients with hematologic malignancies as in those with solid or central nervous system tumors, but by 30 days, that difference was narrowing, and by 1 year, the mortality rate was nearly equivalent between patients with hematologic and solid tumors.[17] This may reflect the fact that by 30 days or 1 year, one can no longer confidently attribute mortality to the hemorrhagic event; death may instead be a result of complications of the malignancy itself.

Morbidity was also higher in (Tables S7 and S9), patients with hematologic malignancies. They had significantly longer hospital stays (OR = 13.45, 95% CI = 2.86-63.22, \( P = 0.001 \)) in the univariate analysis) and more frequent ICU admissions (OR = 1.88, 95% CI = 1.39-2.55, \( P < 0.001 \)). Longer hospital stays in liquid tumor patients may also be a result of their vulnerability to infection or inpatient administration of chemotherapeutics. Nevertheless, the increased frequency of ICU admissions undoubtedly reflects greater disease severity. We assumed this higher morbidity and mortality to be due
to underlying thrombocytopenia; in our multivariable analysis of in-hospital mortality, every incremental drop in platelet count of 10 increased the mortality risk by 4%, and we know that patients with hematologic malignancies often have platelet counts below 50, with some cases reaching below 20. Indeed, our patients with platelet counts <50 had around three fold risk of in-hospital mortality (OR = 3.41, 95% CI = 2.24-5.23, \( P < 0.001 \)), 7-day mortality (OR = 2.57, 95% CI = 1.60-4.13, \( P < 0.001 \)) and 30-day mortality (OR = 2.24, 95% CI = 1.57-3.19, \( P < 0.001 \)). Patients with platelet counts <50 had also higher likelihood of ICU admission (OR = 2.22, 95% CI = 1.60-3.09, \( P < 0.001 \)) and longer hospital length of stay (OR = 27.96, 95% CI = 5.20-150.4, \( P < 0.001 \)).

Nearly half of our patients with ICH presented with headache, either alone or accompanied with other symptoms such as altered mental status. There is little debate that new neurologic deficits require imaging in the ED, but in the general population, judicious use of imaging to evaluate headache is recommended using clinical decision tools such as the Canadian computed tomography head rule or the Ottawa subarachnoid hemorrhage [21, 24]. In the cancer population, such screening is not validated, and the frequency of ICH in patients presenting with non-focal symptoms such as headache or altered mental status makes bypassing imaging risky.

In fact, diagnostic imaging findings proved to be an important predictive variable for outcomes. Herniation and hydrocephalus were the most significant worrisome radiologic findings predicting short-term mortality, yet both were much less common than cerebral edema and/or midline shift. Intra-metastatic bleeding seems to confer a lower risk of mortality compared with other risks such as hematologic malignancy, active cancer or therapy, and dysrhythmia. Although associated edema was greater for bleeding within tumors, there was less midline shift and herniation (Table S4).

Management of ICH in our cancer patients reflected the etiology of their bleeds. Less invasive interventions such as platelet or dexamethasone administration were most frequent, and surgical interventions were uncommon (11.7%). Few of our patients (9) were on anticoagulants requiring reversal agents such as protamine or Vitamin K (Table S6). Similarly, use of hemostatic agents such as prothrombin complex concentrate (Kcentra), Factor VIIa or tranexamic acid was not reported. The rationale for such conservative management is not always clear; it may reflect a palliative approach in patients with a poor prognosis from advanced cancer, or it may be that thrombocytopenia was the more common problem.

The analysis of risk factors for poor outcomes is perhaps the most significant contribution of this study. Hypertension, a well-established risk factor for ICH in the general population, was also present in nearly half of our cancer patient and was associated with longer hospital stays and higher ICU admission rates. In contrast, intratumor bleeding, unique to cancer patients, was associated with the shorter length of hospital stay in the univariate analysis and with reduced ICU admission rates.

Dysrhythmia and anti-coagulant use were also predictive of poorer outcomes. The fatality of ICH in non-cancer patients receiving anticoagulation therapy has been shown to often exceed 30% (prior to the use of direct-acting oral anticoagulants [DOACs] and low-molecular-weight heparin (LMWH)) [20]. One
presumes cancer patients frequently receive anticoagulants owing to the increased incidence of venous thromboembolism (VTE) in malignancy,[19] which is estimated to be as high as 12.6% [13]. Patients receiving anticoagulants have been shown to have increased morbidity and mortality due to secondary hematoma expansion [1, 8, 9]. Yet in one large series of ICH in cancer patients, anticoagulation therapy did not confer higher mortality, even though more patients (19% compared with 13.8%) were receiving anticoagulants in that series than in the current study [18]. Similarly, in a 2017 comparison of outcomes of ICH in patients with and without cancer, few were receiving anticoagulants (8.1% in patients with cancer, 6.9% in those without) [17]

Our patients were screened for all available anti-coagulants (Table S9), yet only enoxaparin was used with any frequency (12.8% compared with 1.3% for warfarin), and no patients were receiving rivaroxaban or apixaban, reflecting the standard treatment for VTE during the period studied. One cannot conclude from these data whether the low association between anticoagulation therapy and poor outcomes is due to judicious use of anticoagulants in this vulnerable population or due to the inherently lower risk of bleeding of these anticoagulants.

Thrombocytopenia significantly raised the risk of in-hospital, 7-day, and 30-day mortality. For each 10-unit drop in platelet count, the risk of in-hospital mortality rose by 4%, the risk of 7-day mortality by 3%, and the risk of 30-day mortality by 10% (Figure 2). Many of our cancer patients had severe thrombocytopenia due to chemotherapy or the malignancy itself, as in leukemia. The risk of spontaneous hemorrhage in severe thrombocytopenia is well recognized, and this is the rationale behind prophylactic platelet transfusions. Our study showed that thrombocytopenia remains one of the major contributors to poor outcome as measured by 7, 30 day, in-hospital mortality, ICU admission and hospital LOS (Tables 3, S5, and S7 and Figure 2), despite best practices in prophylaxis [4, 11, 16]. Anemia was also common in our patient population and increased mortality risk presumably owing to decreased oxygen-carrying capacity to the threatened brain tissue. Low hemoglobin levels at the time of acute ischemic stroke are associated with larger infarcts and increased infarct growth [14, 22].

In the decade since the last study of ICH in cancer patients, many new therapies have increased the lifespan of patients with liquid tumors, and new anticoagulant classes such as low-molecular-weight heparin have made anticoagulation therapy safer compared with vitamin K inhibitors. Concomitantly, targeted and immune-mediated therapies have decreased the incidence of treatment-related coagulopathies. Perhaps this has been protective against the risk and/or severity of ICH in cancer patients. Although 66.9% of our patients were on active therapy, and over 90% had either stage IV cancer or a hematologic malignancy, our in-hospital mortality was only 15.1% - and 30-day mortality 25.6%.

**Limitations**

Our large sample size mitigates against many study biases, but some remained. Foremost, this was a single-center retrospective study with a singular patient population and perhaps treatment preferences, although our demographics were very similar to those of previous studies [17, 18]. We had only surrogate markers for severity of neurologic dysfunction upon presentation, and because this was a retrospective
study, the Glasgow Coma Scale or Rankin scores for objectively measuring the clinical severity of the bleed were not consistently available, so we could reliably report only mortality. Similarly, the presenting symptoms lacked specificity, for example not distinguishing between focal paresis and generalized weakness. Our objective data and radiographic, medication, and laboratory findings, however, generated solid multivariable analyses. We used pharmacy data of anti-coagulant use as a surrogate for coagulopathy, which does not account for all causes of coagulopathy that can be measured by prothrombin time, partial thromboplastin time, thrombin time and fibrinogen. Although patients with intratumor or primary brain bleeding appeared to have lower mortality rates, the $P$ value did not reach significance, perhaps because the number of patients in this subgroup was inadequate.

As discussed, the period studied was before the advent of DOACs for the treatment of VTE in cancer and atrial fibrillation, so we could not incorporate the presumed decreased risk of ICH. We were able to associate ICH risk factors with outcomes but not prevalence of ICH because we did not have the denominator of all patients with and without ICH for particular risk factors. We do not have data on the frequency of repeat ED visits for specific malignancies, or proportionally how many were being treated at MD Anderson. Finally, not all the cancer patients with ICH presented at our ED; some went to other hospitals, some bypassed the ED when admitted, and some, presumably the least symptomatic, may never have been diagnosed at all. Nevertheless, we believe the outcomes data offered here will help stratify the risk of morbidity and mortality in cancer patients presenting with ICH.

**Conclusion**

ICH remains an uncommon diagnosis among the ailments that bring cancer patients to the ED. In our cohort, in-hospital, 7-day, and 30-day mortality rates were lower than previously reported, and about two-thirds of patients were discharged to home, suggesting limited morbidity or disability from their hemorrhage. Among the multiple known risk factors and clinical characteristics of ICH, the ones most helpful in predicting patient outcomes were hypertension, low platelet count, and diagnostic imaging. Understanding how the clinical presentation, risk factors, and imaging findings correlate with patient morbidity and mortality is helpful in guiding diagnostic evaluation of ICH and the aggressiveness of care.

**Declarations**

**Funding:** None

**Conflicts of interest/Competing interests:** Dr. Yeung had research funding by DepoMed, Inc. and Bristol-Myer Squibb, and was on an advisory board for Celgene Corporation. All other authors declare no competing financial or non-financial interests.

**Acknowledgments:** The authors thank Erica Goodoff, ELS, from the Research Medical Library at The University of Texas MD Anderson Cancer Center, and Jayne Viets-Upchurch, MD for editing this manuscript. The authors also thank Rachel S. Hicklen for reference library support.
Authors contribution: AHW, SJY, AQ conceived and designed the study and developed the methods. AHW, AQ, PS, MK acquired data. ZL supervised statistical analysis. AHW, AQ, SJY, CMR analyzed and interpreted the data. AHW, AQ, SJY, CMR drafted the manuscript. All authors reviewed and provided final approval of the manuscript.

Ethics approval: The University of Texas MD Anderson Office of Human Subject Protection institutional review board approved this study under the protocol: PA17-0147_MOD003. It granted waiver of informed consent as the study is a blinded and retrospective with no identification of individual participants. All relevant guidelines and regulations were followed. Informed consent was waived by the Institutional Review Board of the Office of Human Subject Protection at The University of Texas MD Anderson Cancer Center, Chair Designee, Kara M. Seales.

References

1. Adachi T, Hoshino H, Takagi M, Fujioka S (2017) Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin. Cerebrovascular diseases extra 7:62-71

2. An SJ, Kim TJ, Yoon BW (2017) Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. Journal of stroke 19:3-10

3. Carney BJ, Uhlmann EJ, Puligandla M, Mantia C, Weber GM, Neuberg DS, Zwicker JI (2019) Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. Journal of thrombosis and haemostasis: JTH 17:72-76

4. Chern JJ, Tsung AJ, Humphries W, Sawaya R, Lang FF (2011) Clinical outcome of leukemia patients with intracranial hemorrhage. Clinical article. Journal of neurosurgery 115:268-272

5. Chu KH, Mahmoud I, Hou XY, Winter CD, Jeffree RL, Brown NJ, Brown AF (2018) Incidence and outcome of subarachnoid haemorrhage in the general and emergency department populations in Queensland from 2010 to 2014. Emergency medicine Australasia : EMA 30:503-510

6. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G (2011) Prediction model for mortality after intracranial hemorrhage in patients with leukemia. American journal of hematology 86:546-549

7. Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, Zwicker JI (2015) Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood 126:494-499

8. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J (2004) Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 63:1059-1064
9. Frontera JA, Lewin JJ, 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL (2016) Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocritical care 24:6-46

10. Garg R, Biller J (2019) Recent advances in spontaneous intracerebral hemorrhage. F1000Research 8

11. Gaydos L, Freireich E, Mantel N (1962) The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. The New England journal of medicine 266:905-909

12. González-Pérez A, Gaist D, Wallander MA, McFeat G, García-Rodríguez LA (2013) Mortality after hemorrhagic stroke: data from general practice (The Health Improvement Network). Neurology 81:559-565

13. Khorana AA, Dalal M, Lin J, Connolly GC (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119:648-655

14. Kimberly WT, Wu O, Arsava EM, Garg P, Ji R, Vangel M, Singhal AB, Ay H, Sorensen AG (2011) Lower hemoglobin correlates with larger stroke volumes in acute ischemic stroke. Cerebrovascular diseases extra 1:44-53

15. Krishnamurthi RV, Moran AE, Forouzanfar MH, Bennett DA, Mensah GA, Lawes CM, Barker-Collo S, Connor M, Roth GA, Sacco R, Ezzati M, Naghavi M, Murray CJ, Feigin VL (2014) The global burden of hemorrhagic stroke: a summary of findings from the GBD 2010 study. Global heart 9:101-106

16. Mayda-Domac F, Misirli H, Yilmaz M (2010) Prognostic role of mean platelet volume and platelet count in ischemic and hemorrhagic stroke. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 19:66-72

17. Murthy SB, Shastri A, Merkler AE, Hanley DF, Ziai WC, Fink ME, Iadecola C, Kamel H, Navi BB (2016) Intracerebral Hemorrhage Outcomes in Patients with Systemic Cancer. J Stroke Cerebrovasc Dis 25:2918-2924

18. Navi BB, Reichman JS, Berlin D, Reiner AS, Panageas KS, Segal AZ, DeAngelis LM (2010) Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology 74:494-501

19. Qdaisat A, Wu W, Lin JZ, Al Soud R, Yang Z, Hu Z, Gao S, Wu CC, Liu X, Silvestre J, Hita AG, Viets-Upchurch J, Al Adwan S, Al Haj Qasem N, Cruz Carreras MT, Jacobson KL, Chaftari PS, Abdel-Razeq H, Reyes-Gibby CC, Jim Yeung SC (2020) Clinical and Cancer-Related Predictors for Venous Thromboembolism in Cancer Patients Presenting to the Emergency Department. J Emerg Med 58:932-941
20. Qureshi AI, Mendelow AD, Hanley DF (2009) Intracerebral haemorrhage. Lancet (London, England) 373:1632-1644

21. Stiell IG, Wells GA, Vandemheen K, Clement C, Lesiuk H, Laupacis A, McKnight RD, Verbeek R, Brison R, Cass D, Eisenhauer ME, Greenberg G, Worthington J (2001) The Canadian CT Head Rule for patients with minor head injury. Lancet (London, England) 357:1391-1396

22. Tanne D, Molshatzki N, Merzeliak O, Tsabari R, Toashi M, Schwammenthal Y (2010) Anemia status, hemoglobin concentration and outcome after acute stroke: a cohort study. BMC neurology 10:22

23. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ (2010) Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. The Lancet Neurology 9:167-176

24. Wu WT, Pan HY, Wu KH, Huang YS, Wu CH, Cheng FJ (2020) The Ottawa subarachnoid hemorrhage clinical decision rule for classifying emergency department headache patients. The American journal of emergency medicine 38:198-202

25. Zwicker JI, Karp Leaf R, Carrier M (2016) A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. Journal of thrombosis and haemostasis : JTH 14:1736-1740

Tables

Due to technical limitations, table 1-4 is only available as a download in the Supplemental Files section.

Figures
Figure 1

Exclusion criteria used to determine study eligibility. Abbreviations: ICH, intracranial hemorrhage.

| Variable                  | In-hospital mortality | 7-day mortality | 30-day mortality |
|---------------------------|-----------------------|-----------------|------------------|
|                           | Odds ratio | OR (95% CI) | P     | Odds ratio | OR (95% CI) | P     | Odds ratio | OR (95% CI) | P     |
| Age                       |            |              |       |            |              |       |            |              |       |
| Less than 65 years        | Reference  | 1.01 (0.65-1.60) | 0.960 | Reference  | 0.82 (0.50-1.35) | 0.431 | Reference  | 0.91 (0.53-1.52) | 0.615 |
| 65 years or more          |            |              |       |            |              |       |            |              |       |
| Cancer type               |            |              |       |            |              |       |            |              |       |
| Solid                     | Reference  | 1.08 (0.63-1.89) | 0.776 | Reference  | 0.89 (0.44-1.44) | 0.459 | Reference  | 0.82 (0.35-1.97) | 0.376 |
| Hematologic               |            |              |       |            |              |       |            |              |       |
| Cancer status             |            |              |       |            |              |       |            |              |       |
| Active                    | Reference  | 0.72 (0.34-1.44) | 0.392 | Reference  | 0.81 (0.24-1.34) | 0.260 | Reference  | 0.69 (0.30-1.59) | 0.106 |
| Stable                    |            |              |       |            |              |       |            |              |       |
| Active cancer therapy     |            |              |       |            |              |       |            |              |       |
| No                        | Reference  | 0.92 (0.57-1.51) | 0.736 | Reference  | 1.03 (0.50-1.92) | 0.916 | Reference  | 1.20 (0.51-3.06) | 0.235 |
| Yes                       |            |              |       |            |              |       |            |              |       |
| Dyshrhythmia              |            |              |       |            |              |       |            |              |       |
| No                        | Reference  | 1.56 (0.73-3.14) | 0.227 | Reference  | 1.82 (0.83-3.74) | 0.116 | Reference  | 1.19 (0.62-2.20) | 0.590 |
| Yes                       |            |              |       |            |              |       |            |              |       |
| Intratumor bleeding       |            |              |       |            |              |       |            |              |       |
| No                        | Reference  | 0.54 (0.28-0.99) | 0.052 | Reference  | 0.58 (0.30-1.09) | 0.008 | Reference  | 1.17 (0.75-1.83) | 0.407 |
| Yes                       |            |              |       |            |              |       |            |              |       |
| Platelet count*           |            |              |       |            |              |       |            |              |       |
| No                        | Reference  | 0.98 (0.94-0.99) | 0.008 | Reference  | 0.97 (0.95-1.00) | 0.062 | Reference  | 0.99 (0.96-1.00) | 0.016 |
| Yes                       |            |              |       |            |              |       |            |              |       |
| Hemoglobin level          |            |              |       |            |              |       |            |              |       |
| No                        | Reference  | 0.96 (0.85-1.07) | 0.451 | Reference  | 0.98 (0.87-1.11) | 0.815 | Reference  | 0.90 (0.82-0.98) | 0.019 |

Figure 2
Multivariable analysis of the association between clinical factors and short-term mortality in cancer patients with intracranial hemorrhage. Platelet count was calculated as a continuous variable in increments of 10. Abbreviations: OR, odds ratio; CI, confidence interval.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- ICHSupplementaldata.scientificreports.docx
- Tables.pdf